A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02329327
Recruitment Status : Recruiting
First Posted : December 31, 2014
Last Update Posted : September 25, 2018
Population Health Research Institute
Information provided by (Responsible Party):
Portola Pharmaceuticals